Background: The impact of genetic polymorphisms on cognition is assumed to increase with age as losses of brain resources have to be compensated for. We investigate the relation of catechol-O-methyltransferase (COMT)p.Val158Met polymorphism and cognitive capacity in the course of adult development, healthy aging and the development of mild cognitive impairment (MCI) in two birth cohorts of subjects born between 1930 and 1932 or between 1950 and 1952. Methods: Thorough neuropsychological assessment was conducted in a total of 587 participants across three examination waves between 1993 and 2008. The COMT genotype was determined as a restriction fragment length polymorphism after PCR amplification and digestion with Nla III. Results: Significant effects of the COMTp.Val158Met polymorphism were identified for attention and cognitive flexibility in the younger but not the older cohort. Conclusion: These results confirm the importance of the COMTp.Val158Met genotype on tasks assessing attention and cognitive flexibility in midlife but not in healthy aging and the development of MCI. Our findings suggest that the influence of COMT changes as a function of age, decreasing from midlife to aging.

1.
Backman L, Nyberg L, Lindenberger U, Li S, Farde L: The correlative triad among aging, dopamine, and cognition: current status and future prospects. Neurosci Biobehav Rev 2006;30:791-807.
2.
Mattay VS, Goldberg TE: Imaging genetic influences in human brain function. Curr Opin Neurobiol 2004;14:239-247.
3.
Egan M, Goldman D, Weinberger D: The human genome: mutations. Am J Psychiatry 2002;159:12.
4.
Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D, Weinberger DR: Effect of COMT Val108/158Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001;98:6917-6922.
5.
Savitz J, Solms M, Ramesar R: The molecular genetics of cognition: dopamine, COMT and BDNF. Genes Brain Behav 2006;5:311-328.
6.
Sheldrick AJ, Krug A, Markov V, Leube D, Michel TM, Zerres K, Eggermann T, Kircher T: Effect of COMT val158met genotype on cognition and personality. Eur Psychiatry 2008;23:385-389.
7.
Malhotra AK, Kestler LJ, Mazzanti C, Bates JA, Goldberg T, Goldman D: A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 2002;159:652-654.
8.
Bruder GE, Keilp JG, Xu H, Shikhman M, Schori E, Gorman JM, Gilliam TC: Catechol-O-methyltransferase (COMT) genotypes and working memory: associations with differing cognitive operations. Biol Psychiatry 2005;58:901-907.
9.
Barnett JH, Scoriels L, Munafo MR: Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism. Biol Psychiatry 2008;64:137-144.
10.
Ho B, Wassink TH, O'Leary DS, Sheffield VC, Andreasen NC: Catechol-O-methyl transferase Val158Met gene polymorphism in schizophrenia: working memory, frontal lobe MRI morphology and frontal cerebral blood flow. Mol Psychiatry 2005;10:287-298.
11.
Lindenberger U, Nagel IE, Chicherio C, Li S, Heekeren HR, Bäckman L: Age-related decline in brain resources modulates genetic effects on cognitive functioning. Front Neurosci 2008;2:234-244.
12.
Nagel IE, Chicherio C, Li S, von Oertzen T, Sander T, Villringer A, Heekeren HR, Bäckman L, Lindenberger U: Human aging magnifies genetic effects on executive functioning and working memory. Front Hum Neurosci 2008;2:1-8.
13.
De Frias CM, Annerbrink K, Westberg L, Eriksson K, Adolfsson R, Nilsson LG: Catechol O-methyltransferase Val158Met polymorphism is associated with cognitive performance in nondemented adults. J Cogn Neursci 2005;17:1018-1025.
14.
Fiocco AJ, Lindquist K, Ferrel R, Li R, Simonsick EM, Nalls M, Harris TB, Yaffe K: COMT genotype and cognitive function: an 8-year longitudinal study in white and black elders. Neurology 2010;74:1296-1302.
15.
Erickson KI, Kim JS, Suever BL, Voss MW, Francis BM, Kramer AF: Genetic contributions to age-related decline in executive function: a 10-year longitudinal study of COMT and BDNF polymorphisms. Front Hum Neurosci 2008;2:11.
16.
Starr JM, Fox H, Harris SE, Deary IJ, Whalley LJ: COMT genotype and cognitive ability: a longitudinal aging study. Neurosci Lett 2007;421:57-61.
17.
Aguilera M, Barrantes-Vidal N, Arias B, Moya J, Villa H, Ibanez MI, Ruiperez MA, Ortet G, Fananas L: Putative role of the COMT gene polymorphism (Val158Met) on verbal working memory functioning in a healthy population. Am J Med Genet B Neuropsychiatr Genet 2008;147B:898-902.
18.
Schröder J, Buchsbaum MS, Shihabuddin L, Tang C, Wei T-C, Spiegel-Cohen J, Hazlett EA, Abel L, Luu-Hsia C, Ciaroavolo TM, Marin D, Davis KL: Patterns of cortical activity and memory performance in Alzheimer's disease. Biol Psychiatry 2001;49:426-436.
19.
Schröder J, Kratz B, Pantel J, Minnemann E, Lehr U, Sauer H: Prevalence of mild cognitive impairment in an elderly community sample. J Neural Transm Suppl 1998;54:51-59.
20.
Schönknecht P, Pantel J, Kruse A, Schröder J: Prevalence and natural course of aging-associated cognitive decline in a population-based sample of young-old subjects. Am J Psychiatry 2005;162:2071-2077.
21.
Levy R: Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization. Int Psychogeriatr 1994;6:63-68.
22.
Wittchen H, Zaudig M, Schramm E, Spengler P, Mombour W, Klug J, Horn R: Strukturiertes klinisches Interview für DSM-III-R. Weinheim, Beltz-Test, 1991.
23.
Lachman HM, Papolos DF, Saito T, et al: Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996;6:243-250.
24.
Oswald W, Fleischmann V: Nürnberger Alters-Inventar. Erlangen, Universität Erlangen-Nürnberg, 1991.
25.
Tewes U (ed): HAWIE-R: Hamburg-Wechsler-Intelligenztest für Erwachsene. Revision 1991. Handbuch und Testanweisung. Bern, Hans Huber, 1991.
26.
Sturm W, Willmes K, Horn W: Leistungsprüfsystem für 50-90jährige. Göttingen, Hogrefe, 1993.
27.
Brickenkamp R: Test d2: Aufmerksamkeits-Belastungstest. Göttingen, Hogrefe, 1978.
28.
Dennis NA, Need AC, LaBar KS, Waters-Metenier S, Cirulli ET, Kragel J, Goldstein DB, Cabeza R: COMT val108/158met genotype affects neural but not cognitive processing in healthy individuals. Cereb Cortex 2010;20:672-683.
29.
Blasi G, Mattay VS, Bertolino A, Elvevag B, Callicott JH, Das S, Kolachana BS, Egan MF, Goldberg TE, Weinberger DR: Effect of catechol-O-methyltransferase val158met genotype on attentional control. J Neurosci 2005;25:5038-5045.
30.
Harris SE, Deary IJ: The genetics of cognitive ability and cognitive ageing in healthy older people. Trends Cogn Sci 2011;15:388-394.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.